4.7 Article

Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype

期刊

NEUROLOGY
卷 77, 期 22, 页码 1965-1971

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31823a0c7f

关键词

-

资金

  1. NICHD [P0I-HD32062]
  2. CTSA [1-ULI-RR024156]
  3. Irving Research Scholar Award
  4. Marriott Mitochondrial Disorder Clinical Research Fund
  5. Colleen Giblin Foundation
  6. Santhera Pharmaceuticals
  7. Penwest Pharmaceuticals Co.
  8. PTC Therapeutics, Inc.
  9. NIH/NINDS
  10. US Department of Defense
  11. SMA Foundation
  12. Canadian Institutes of Health Research
  13. UCB
  14. NIH/NINDS Neurological Science Academic Development
  15. Spinal Muscular Atrophy Foundation
  16. American Academy of Neurology Foundation
  17. NIH (NIA/NCRR)
  18. American College of Medical Genetics
  19. Edison Pharmaceuticals, Inc.
  20. NIH
  21. Muscular Dystrophy Association USA
  22. Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF)
  23. Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRE)
  24. NIH (NINDS, NICHD)
  25. Will Foundation
  26. Pediatric Neurotransmitter Disease Association

向作者/读者索取更多资源

Objective: To describe the natural history of clinical and laboratory features associated with the m.3243A>G mitochondrial DNA point mutation. Natural history data are needed to obtain prognostic information and for clinical trial planning. Methods: We included 85 matrilineal relatives from 35 families with at least 2 visits in this prospective cohort study. Thirty-one were fully symptomatic with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and 54 were carrier relatives. Evaluations included standardized questionnaires (medical history and daily living functioning), physical examination, neuropsychological testing, and a battery of imaging and laboratory tests. We evaluated changes in clinical and laboratory features over time and survival. Outcomes are reported over a follow-up period of up to 10.6 years (mean 3.8 +/- 2.2 years for patients and 5.5 +/- 3.0 for carrier relatives). Results: Neurologic examination, neuropsychological testing, and daily living scores significantly declined in all patients with MELAS, whereas no significant deterioration occurred in carrier relatives. Cerebral MRI scores declined significantly in patients with MELAS. Magnetic resonance spectroscopy estimates of lactate in the lateral ventricles increased over time, and high lactate was associated with increased mortality. Symptom onset in childhood often was associated with worse outcome. Patients with MELAS had a greater death rate than carrier relatives. Conclusions: Patients with MELAS carrying the m.3243A>G mutation show a measurable decline in clinical and imaging outcomes. It is hoped that these data will be helpful in anticipating the disease course and in planning clinical trials for MELAS. Neurology (R) 2011;77:1965-1971

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据